June 5, 2025 (Teva Pharmaceutical Industries Ltd. (via LinkedIn)) –
Teva Pharmaceutical Industries Ltd. posted 31 LinkedIn updates from May 29 to June 5, 2025. The company's posts covered a wide range of topics, including strategic developments, sustainability initiatives, research and development efforts, and corporate social responsibility. Let's explore the key areas of focus for Teva during this period.
Strategic Transformation and Growth
Teva is entering a new phase in its transformation strategy, as announced during their Innovation & Strategy Day. The company has reported nine consecutive quarters of growth and is now accelerating its evolution into a leading biopharma company. CEO Richard Francis emphasized the focus on transforming Teva into a leading biopharmaceutical company enabled by their generics business. The company presented its roadmap to 2027 and beyond, highlighting strong momentum across all strategic pillars.
Brad Loncar of BiotechTV interviewed CEO Richard Francis, discussing the progress update from their Pivot to Growth strategy and the next phase focused on Acceleration. Teva showcased its strong innovative pipeline with multiple late-stage assets that hold blockbuster potential.
Teva enters next phase of transformation
CEO discusses Acceleration phase strategy
Interview highlights strong innovative pipeline
Research and Development Initiatives
Teva presented important updates from its Tardive Dyskinesia (TD) innovative medicines portfolio at a conference in Las Vegas. The company shared data from the long-term care setting for TD management and real-world claims data evaluating relapse rates with long-acting injectables versus daily oral options in schizophrenia. These presentations underscore Teva's commitment to understanding and addressing complex neurological conditions.
The company also offered a glimpse into the daily life of its R&D team through the experience of Inbal Ben-Eliezer, who leads the non-clinical pharmacology lab. This insight showcases Teva's focus on advancing immunology research and testing new compounds, emphasizing the purpose-driven nature of their work.
TD portfolio updates at Las Vegas conference
Day in the life of Teva R&D
Sustainability and Environmental Initiatives
Teva has made significant strides in its sustainability efforts, surpassing its 2025 target for reducing greenhouse gas emissions two years ahead of schedule. The company has cut emissions from its operations by 29% (2024 vs. 2019), bringing it closer to its 2045 goals. This achievement spans 48 manufacturing sites and 21 R&D sites globally, demonstrating Teva's commitment to cleaner energy and more efficient operations.
In the Netherlands, Teva is celebrating the upcoming installation of its 600th Teva Retourbox, a system designed to responsibly dispose of medication waste and prevent pharmaceutical residues from entering surface water. This initiative, implemented in pharmacies and hospitals, showcases Teva's proactive approach to environmental protection.
Teva surpasses 2025 emissions reduction target
600th Teva Retourbox to be installed in Netherlands
Educational and Professional Development Programs
Teva has strengthened its partnership with the University of Debrecen's Faculty of Pharmacy in Hungary. The collaboration includes new types of involvement in teaching work and an expansion of the "Teva for Knowledge and Talent" scholarship program to include PhD students. This initiative provides financial support, deeper insights into the pharmaceutical industry, unique courses, and career opportunities in research and development and manufacturing.
In Germany, Teva successfully concluded the second edition of the Teva Biotech Academy, a development and training program created in collaboration with the International School of Management. The program supports employees in expanding their leadership skills, effectively leading teams, and developing personally and professionally.
Enhanced partnership with University of Debrecen
Teva Biotech Academy concludes successfully
Health Awareness and Patient Support
Teva has been active in raising awareness about various health conditions. For World Multiple Sclerosis Day, the company participated in planting sunflowers in Prague's Kateřinská Garden, alongside patients and doctors from the MS Center of the Neurology Clinic. The event included educational lectures on diagnostics and the importance of patient registries.
The company also promoted awareness about migraine management, announcing the 7th Nordic Migraine Symposium to be held in Oslo, Norway. Additionally, Teva supported the third edition of InnovaMigraine in Italy, an event for young clinicians under 40 to apply their knowledge of migraine treatment through practical activities and group work.
World MS Day awareness event in Prague
Nordic Migraine Symposium announcement
InnovaMigraine event for young clinicians
Employee Well-being and Development
Teva has introduced a sabbatical program for its employees, offering them the opportunity to take time off for personal growth, travel, or further education. The company shared experiences of employees who have taken advantage of this program, highlighting how it has led to personal growth, new perspectives, and renewed energy upon returning to work.
Teva's sabbatical program enhances employee well-being
In conclusion, Teva Pharmaceutical Industries Ltd.'s LinkedIn activity during this period reflects a company deeply committed to strategic growth, innovation in research and development, sustainability, education, and employee well-being. From accelerating its transformation into a leading biopharma company to surpassing environmental goals and fostering educational partnerships, Teva continues to position itself as a leader in the pharmaceutical industry, driving positive change on multiple fronts.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistribute or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.